The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics. Brain Waves: The field of neurotechnology, the focus of this blog, encompasses advances in brain science (neurons), information technology (bits) and bioengineering (genes). Up for discussion and analysis: the political, economic, ethical, and social forces that will shape the future of what will be one of the most important and fascinating stories of the coming decades.

About this author

Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev

Receive by email

GUEST AUTHOR ARCHIVES

In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

« Neuropharma FDA Approvals Down in 2009 | Main | McGovern Institue for Brain Research at MIT Goes Web 2.0 »

February 9, 2010

The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics

Posted by Zack Lynch

We've recently published "The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics," a report published by NeuroInsights. It is a fully updated second annual industry insider report detailing markets and emerging diagnostics in neurology and psychiatry. In addition to the massive unmet markets, long-term growth in neurodiagnostics is being driven by technology advances and equipment upgrades in neuroimaging; new biomarkers and imaging protocols for early diagnosis and disease monitoring; and increased use of imaging and informatics in drug and device development.

NeuroInsights has identified three primary markets in neurodiagnostics which are discussed in detail in this report: Neuroimaging: Medical equipment and reagents for research, diagnostics and patient monitoring, including MRI, CT, PET, SPECT, EEG and MEG. In vitro diagnostics: Genetic testing, biomarker assays and chemical profiling of human samples, including urine, blood, cerebral spinal fluid and tissue. Neuroinformatics: Multidimensional databases and software systems that store and analyze data from the genetic to the behavioral level.

Partial list of companies discussed in the report include: Abbot Diagnostics, Adlyfe, Advanced Brain Monitoring, Applied NeuroSolutions, Aspect Medical (Covidien), Astro-Med, Athena Diagnostics, Avacta, Avid Radiopharmaceuticals, Bayer, BioBehavioral Diagnostics, Brain Resource, BrainScope, Cambridge Cognition, CNS Response, CNS Vital, CogState, Compumedics, Cytox, Electrical Geodesics, Elminda, ExonHit, GE, GeneNews, g-Nostics, Hitachi, Johnson & Johnson, Kappametrics, Knopp Neurosciences, Michael J. Fox Foundation, Natus Medical, NeuroMetrix, Neuronetrix, Neuroptix, NeuroTrax, NeuroVigil, NeuroVista, Nymox, Odin, Optima Neuroscience, Optimal Medicine, Orasi Medical, Ortho-Clinical Diagnostics, Pfizer, Philips, PhysioSonics, Pritzker Neuropsychiatric Consortium, Psynova, Quest Diagnostics, Roche, Rules-Based, Medicine, Satoris, Siemens, SleepMed, The Genetics Company, TheraGenetics, Toshiba,Transcription Diagnostics, Vanda, Wyeth and more. To view the full list of 150 companies included in this extensive report, click here.

Comments (0) + TrackBacks (0) | Category: Neurodiagnostics

POST A COMMENT

Thanks for signing in, . Now you can comment. (sign out)

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)